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Diagnosis of Hepatitis C
ANNA S. F. LOK AND NARESH T. GUNARATNAM
Currently, the second- and third-generation enzyme immu- infection, assessment of the severity of liver disease, monitor-
noassays (EIA-2 and EIA-3) for hepatitis C virus antibody ing progress of liver disease, determination of the likelihood
(anti-HCV) are the most practical screening tests for the diag- of response to interferon therapy, and monitoring of response
nosis of HCV infection. The need for and the choice of supple- to treatment.
mentary or confirmatory tests depend on the clinical setting
and the likelihood of a true-positive EIA result. Detection of DIAGNOSIS OF HEPATITIS C
HCV RNA in serum by polymerase chain reaction (PCR) assay
Anti-HCV Tests. Currently, the second-generation enzymeis the gold standard for the diagnosis of HCV infection. How-
immunoassays (EIA-2) for anti-HCV are the most practicalever, the lack of uniformity in current PCR assays has tar-
screening tests for the diagnosis of HCV infection in thenished this standard. Confirmatory tests for the diagnosis of
United States.1,2 These assays detect antibodies to recombi-HCV infection are in general unnecessary in anti-HCV–posi-
nant HCV antigens from the core (C22) and nonstructuraltive patients who present with chronic liver disease. When
regions 3 (C33) and 4 (C-100). They are easy to performindicated, the most appropriate test in this setting is a qualita-
and the results are highly reproducible. Recently, third-gen-tive PCR assay for HCV RNA. Confirmatory tests should al-
eration EIAs (EIA-3) have been approved by the Food andways be performed in anti-HCV–positive blood donors and
Drug Administration for blood donor screening. EIA-3 differsindividuals with normal aminotransferase levels. The most
from EIA-2 in that it incorporates additional recombinantappropriate approach is to retest for anti-HCV using recombi-
HCV antigen from the nonstructural region 5 (NS5). EIA-3 isnant immunoblot assay (RIBA) and then test for HCV RNA
slightly more sensitive than EIA-2, but most of the improvedusing PCR assay in those who are RIBA positive or indetermi-
sensitivity appears to be attributable to increased detectionnate. Liver histology is the gold standard in assessing severity
of anti-C33 and not the addition of NS5.3-5 The second-of liver disease. Quantitative tests for serum HCV RNA levels
generation recombinant immunoblot assays (RIBA-2) permitdo not help to determine the severity of liver disease. At the
the detection of antibodies to individual recombinant HCVmoment, HCV genotyping should be considered a research
antigens: C22, C33, C-100, and 5-1-1 (overlaps with C-100).tool and not a part of the diagnostic work-up in clinical prac-
Patients who react to two or more HCV antigens are consid-tice. The goals of treatment for chronic hepatitis C are sus-
ered to be RIBA positive, whereas those who react to onetained biochemical and virological response. Viral clearance
HCV antigen only are considered to have indeterminate re-should be determined by qualitative PCR assay. Quantifying
sults.1,2 RIBAs are technically more demanding than EIAs,serum HCV RNA level can help in predicting response to
but they are simpler, more standardized, and more reproduc-interferon treatment, but further studies using more standard-
ible than tests for HCV RNA. RIBAs confer increased specific-ized assays are needed to determine if these values can be
ity compared with EIAs. Nevertheless, RIBA positivity is notused to select patients for treatment. (HEPATOLOGY 1997;26
always indicative of ongoing HCV infection because patients(Suppl 1):48S-56S.)
with recovered HCV infection may remain anti-HCV positive
for many years. RIBA-3, which differs from RIBA-2 in havingDiagnosis of hepatitis C involves confirmation of the pres-
additional recombinant proteins from NS5 and synthetic pep-ence of hepatitis C virus (HCV) infection and assessment of
tides from the core and NS3 antigens, has helped to resolvethe severity of liver disease. In addition, the diagnostic work-
many of the RIBA-2 indeterminate samples, but only approxi-up should include investigations that may help to predict
mately 50% of the RIBA-3–positive blood donors are HCVprognosis and response to treatment. This review focuses on
RNA positive by polymerase chain reaction (PCR) assays.6,7the application of tests for antibody to HCV (anti-HCV),
EIA-3 and RIBA-3 have replaced EIA-2 and RIBA-2 in manyHCV RNA, and HCV genotypes in the diagnosis of HCV
European and Asian countries.
HCV RNA Assays. Confirmation of the diagnosis of ongoing
HCV infection relies on the detection of viremia. This may
Abbreviations: HCV, hepatitis C virus; anti-HCV, antibody to HCV; EIA, enzyme be achieved by qualitative reverse-transcription PCR or
immunoassay; RIBA, recombinant immunoblot assay; PCR, polymerase chain reaction; branched DNA (bDNA) assays. Although the bDNA assay is
bDNA, branched DNA signal amplification assay; ALT, alanine aminotransferase. technically simpler and has a lower chance of cross-contami-
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have undetectable HCV RNA if tested by the bDNA assay.8,10-14
Although the detection of HCV RNA by PCR assays is consid-
ered to be the gold standard for the diagnosis of HCV infec-
tion, the lack of uniformity in current PCR assays has tar-
nished this standard. In a recent international collaborative
study, 86 laboratories submitted 136 data forms on a panel
of coded sera.15 Of these data sets, 99 were tested using
a PCR assay developed in-house, 28 using a commercially
available PCR assay (AMPLICOR; Roche Molecular Diagnos-
tics Systems, Branchburg, NJ), and 9 using other amplifica-
tion methods. Only 16% of the data forms had faultless re-
sults, 29% missed the weak positive sample only, and 55%
had false-positive and/or false-negative results. These data FIG. 1. Algorithm for the diagnostic evaluation of anti-HCV (EIA-2)–
highlight the urgent need to standardize PCR assays for the positive patients with chronic liver disease. Most (ú90%) of these patients
have ongoing HCV infection. Thus, confirmatory tests may not be necessary.detection of HCV RNA. Standardization is especially im-
When indicated, PCR assay for HCV RNA is more appropriate than RIBA.portant for quantitative HCV RNA assays where up to 1,000-
Pos, positive; ind, indeterminate; neg, negative; FU, follow-up.fold differences in HCV RNA levels have been reported.15
HCV Genotyping. There are at least six genotypes of HCV
and more than 30 subtypes. HCV genotyping provides im- cally indicated. Studies performed on recently collected sera
portant information in epidemiological studies but does not in experienced laboratories have yielded HCV RNA detection
help in confirming the diagnosis of HCV infection. rates of greater than 90%.20 Thus, it can be argued that sup-
Liver Biopsy. Characteristic histological features that are plementary and confirmatory tests for the diagnosis of HCV
more frequently found in patients with chronic hepatitis C infection are in general unnecessary in anti-HCV (EIA-2)–
than in patients with chronic hepatitis B or autoimmune positive patients who present with chronic liver disease, espe-
hepatitis have been reported.16-18 However, none of these cially those who have risk factors for HCV infection. When
features is pathognomonic for chronic hepatitis C. Liver bi- confirmatory tests are performed, PCR assays for HCV RNA
opsies are not necessary for the diagnosis of HCV infection. are more appropriate than RIBA. Although qualitative PCR
DIAGNOSTIC ALGORITHMS assay for HCV RNA will suffice to confirm the diagnosis,
quantitative tests may be considered if treatment is contem-The need for and the choice of supplementary and confir-
plated (vide infra) because many studies have found thatmatory tests depend on the clinical setting and the likelihood
pretreatment serum HCV RNA level is the most importantof a true-positive EIA result.9,19 Different diagnostic algo-
independent predictor of response to treatment.rithms may be considered for patients presenting with
Anti-HCV–Positive (EIA-2) Blood Donors and Individuals Withchronic liver disease or elevated alanine aminotransferase
Normal ALT Levels. Contrary to patients with chronic liver(ALT) levels as opposed to asymptomatic blood donors or
disease, only 30% to 40% anti-HCV (EIA-2)–positive bloodindividuals with normal ALT levels. It can also be argued
donors are RIBA positive and 20% to 40% are RIBA indeter-that individuals with or without risk factors for HCV infec-
minate (Fig. 2). The percentage of EIA-2–positive blood do-tion should be evaluated differently. However, identification
nors who have detectable HCV RNA in serum when testedof risk factors is more subjective and dependent on the expe-
by PCR assay varies from 70% to 90% for those who arerience and skills of the clinician. In view of the possibility
RIBA positive to 2% to 40% for those who are RIBA indeter-of a false-negative EIA-2 result, modified diagnostic algo-
minate, to none among those who are RIBA negative, givingrithms are recommended for immunocompromised patients
an overall detection rate of 35% to 45% (Table 1).24-33 Thus,and patients with acute hepatitis C.
supplementary or confirmatory tests for HCV infectionAnti-HCV–Positive (EIA-2) Patients Presenting With Chronic
should always be performed in EIA-2–positive blood donors.Liver Disease or Elevated ALT Level. The majority (78%-98%)
Two algorithms can be considered for the evaluation of EIA-of patients who present with chronic liver disease and are
2–positive blood donors (Fig. 2).anti-HCV positive by EIA-2 have chronic HCV infection as
The first algorithm is to retest for anti-HCV using RIBA,defined by the detection of HCV RNA in serum using PCR
and then test for HCV RNA using PCR assay in those whoassays (Fig. 1).10,20-23 Most (80%-90%) EIA-2–positive pa-
are RIBA positive or indeterminate. RIBA-negative donorstients with chronic liver disease are RIBA positive, 90% of
can be dismissed. PCR-positive donors should be furtherwhom will be HCV RNA positive; approximately 10% are
evaluated to assess the severity of liver disease. The disposi-RIBA indeterminate, 60% to 70% of whom will be HCV RNA
tion of RIBA-positive or -indeterminate donors who are PCRpositive.22,23 Failure to detect HCV RNA in all patients may
negative is less clear. Several studies have found that individ-be related to insensitivity of the PCR assays, degradation of
uals with isolated reactivity to C-100 or 5-1-1 are invariablyHCV RNA during sample collection and storage, intermittent
PCR negative.27,28,33 However, HCV RNA can be detected inviremia, resolved HCV infection, or false-positive EIA result.
0% to 80% of individuals with isolated reactivity to C22 orThese patients should be retested for HCV RNA using the
C33.27,29,34 Histological evidence of chronic hepatitis has beenmost reliable PCR assay available, and attention should be
reported in 7.5% to 18% of RIBA-indeterminate donors,29,35paid to optimize the conditions for sample collection and
but liver disease appeared to be confined to those who werestorage to prevent RNA degradation. Investigations into other
PCR positive. Among RIBA-positive donors, three studiescauses of chronic liver disease should be performed in pa-
tients who are repeatedly HCV RNA negative and when clini- reported that 6 of 29 (21%) PCR-negative donors had chronic
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step approach. However, it is not clear if all the PCR-negative
donors can be safely dismissed because significant liver dis-
ease can be found in PCR-negative donors, predominantly
those who are RIBA positive. Follow-up and retesting of all
the PCR-negative donors (55%-65%) will be more tedious
and expensive than the first algorithm. Clearly, the choice
between the two diagnostic algorithms depends on the avail-
ability of reliable PCR assays that can serve as the gold stan-
dard for the diagnosis of HCV infection. Early studies on
stored sera reported that patients with chronic hepatitis C
may be intermittently PCR negative.38,39 However, more re-
cent studies found that the vast majority of patients with
chronic hepatitis C who are not receiving interferon therapy
are persistently viremic.40,41 Further studies using standard-
ized PCR assays are needed to clarify the frequency of inter-FIG. 2. Algorithm for the diagnostic evaluation of anti-HCV (EIA-2)–
positive blood donors and individuals with normal aminotransferase levels. mittent viremia in untreated patients with chronic HCV in-
Confirmatory tests should always be performed in these individuals. The fection and to determine the prevalence of significant liver
most appropriate approach is to retest for anti-HCV using RIBA and then disease among RIBA-positive, PCR-negative individuals.test for HCV RNA using PCR assay in those who are RIBA positive or
While these data are collected and standardized PCR assaysindeterminate. Direct confirmation using PCR assay is not recommended
because of the poor standardization of current assays. Pos, positive; ind, are developed, the first diagnostic algorithm is preferred for
indeterminate; neg, negative; FU, follow-up. the evaluation of EIA-positive blood donors.
Other individuals who are found to be anti-HCV (EIA-2)–
positive with normal ALT levels should be evaluated using
persistent hepatitis, but none had chronic active hepatitis or the same algorithm for blood donors. Although it is possible
cirrhosis.32,36,37 However, one study found that 17 of 34 that these individuals may have a false-positive EIA test result
(50%) RIBA-positive, PCR-negative donors had chronic hep- or resolved HCV infection, many (especially those who are
atitis, 4 of whom had chronic active hepatitis.30 The high RIBA positive) are viremic, and some may develop elevated
rate of significant liver disease in PCR-negative donors in the ALT levels on follow-up evaluation. Studies in EIA-2–posi-
latter study may be related to insensitivity of the PCR assay tive blood donors found that 40% to 60% had normal ALT
because HCV RNA was detected in only 65% (64 of 98) of levels at the time of blood donation, but 30% to 50% of these
RIBA-positive donors in contrast to the 89% detection rate donors developed intermittent or persistent elevation in ALT
in other studies.27,31 These data suggest that RIBA-indetermi- levels during a 6- to 12-month follow-up period.35,42 Among
nate donors who are PCR negative can be dismissed if the the RIBA-positive blood donors, HCV RNA was detected in
PCR assay is reliable. One might even argue that HCV RNA 55% to 65%30,32 and chronic hepatitis in 30% to 70%30,35,42-44
testing is unnecessary in donors who have isolated reactivity of those with persistently normal ALT levels.
to C100 or 5-1-1. In view of the finding of chronic hepatitis Immunocompromised Patients. Immunocompromised patients
such as hemodialysis patients and transplant recipients havein 21% to 50% of RIBA-positive, PCR-negative donors, re-
impaired antibody response to HCV antigens, especially C-testing for HCV RNA is recommended for these individuals
100 and 5-1-1.45,46 False-negative results in EIA-2 for anti-to exclude the possibility of intermittent viremia or false-
HCV have been reported in 2.5% to 10.5% of patients whonegative result because of suboptimal assay.
were PCR positive.46-49 Thus, tests for HCV RNA should beThe second algorithm is to test all EIA-2–positive blood
performed in immunocompromised patients who are anti-donors for HCV RNA by PCR assay because 60% to 70% will
eventually be tested for HCV RNA. This is potentially a one- HCV negative when there is clinical suspicion of HCV infec-
TABLE 1. RIBA and PCR Testing in Anti-HCV (EIA-2)–Positive Blood Donors
RIBA-2 PCR Positive
No. of % %
Reference Country Donors Positive Indeterminate No. %
Prati26 Italy 483 36 26 170/259 66*
Kleinman27 USA 70 39 30 28/48 58*
Serfaty42 France 483 36 23 NT
Rossini28 Italy 477 36 23 10/40 25†
Prieto30 Spain 975 33 39 64/98 65‡
Salmeron31 Spain 228 63 20 80/126 63*
Mean 40 27 67*
95% Confidence interval 31-49 21-32 60-75*
Abbreviation: NT, not tested.
* RIBA-positive and -indeterminate donors.
† RIBA-indeterminate donors.
‡ RIBA-positive donors.
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tion. In view of the complexity and high costs of PCR assays, hepatocellular carcinoma than in patients with chronic hepa-
titis.24,25,72,74-78 In addition, several studies found a higherit is impractical to recommend HCV RNA testing as the initial
diagnostic test for these patients. Recent studies suggest that prevalence of genotype 1b among patients with chronic liver
disease versus asymptomatic blood donors and individualsEIA-3 is more sensitive and can detect anti-HCV seroconver-
sion earlier than EIA-2 in hemodialysis patients.50,51 These with normal ALT levels.25,26,79 Nevertheless, some of these
studies also noted that patients with genotype 1b weredata need to be confirmed.
Patients With Acute Hepatitis. Anti-HCV, as detected by EIA- older.24,25,72,79,80 Thus, it is possible that longer duration of
infection rather than genotype 1b per se accounted for the2, is positive in approximately 50% of patients with acute
hepatitis C at the time of presentation, and in 90% of patients more advanced liver disease. Other studies have not con-
firmed an association between genotype 1b and the presenceat some point during the acute illness.52 Tests for HCV RNA,
preferably by qualitative PCR assays, permit earlier diagnosis of severe or advanced liver disease.67,81-83 Several reasons may
account for the conflicting data: imbalance in the numberand institution of treatment since several randomized con-
trolled trials have shown that interferon therapy can reduce of patients with each genotype (many studies had very few
patients with non-1b genotypes), failure to include patientsthe rate of chronic infection.53-57
with the full spectrum of liver disease from asymptomatic
ASSESSMENT OF THE SEVERITY OF LIVER DISEASE blood donors with normal ALT levels to hepatocellular carci-
noma (some studies included patients with mild to severeMost patients with acute or chronic hepatitis C have no
or nonspecific symptoms. Thus, history and physical exami- chronic hepatitis only), and different typing techniques (with
the potential for misclassification). All the studies cited abovenation are unreliable in assessing the severity of liver disease,
except in patients with decompensated cirrhosis. were cross-sectional studies.
Two recent studies examined the relation between HCVLiver Biopsy. Liver histology is the gold standard for as-
sessing the severity of liver disease. Liver biopsy is the only genotype and development of progressive liver disease with
opposite conclusions. In one study, 136 Japanese patientsmeans to diagnose well-compensated cirrhosis. It is useful
in determining not only inflammatory activity but also the (96 type 1b, 36 type 2) were followed-up for a mean of
9.6 years (range, 5-26 years). The initial inflammatory andextent of fibrosis. Histological grading of inflammatory activ-
ity and staging of fibrosis have also been shown to correlate fibrosis scores were comparable between patients with types
1 and 2. However, patients with genotype 1 had significantlywith the risk of subsequent progression to cirrhosis.58 In
addition, fibrosis score or cirrhosis has been identified to be higher inflammatory as well as fibrosis scores on the follow-
up biopsies compared with patients with genotype 2.84 Inone of the most important independent predictive factors for
response to interferon treatment.59-63 addition, a significantly higher percentage of patients with
genotype 1 developed hepatocellular carcinoma during fol-Serum Aminotransferase Levels. Although anti-HCV–posi-
tive patients who have elevated ALT levels are more likely low-up (29% vs. 5.6%; P õ .001). These findings differed
from those in a second study in which 85 Italian patientsto have significant liver disease on liver biopsy than those
who have persistently normal ALT levels,25 histological evi- (47 type 1, 30 type 2) were followed-up for a mean of 66.9
months (range, 12-119 months).21 There was no correlationdence of chronic hepatitis can be found in 30% to 70% of
RIBA-2– and PCR–positive individuals despite persistently between HCV genotypes and progression of liver disease,
death, or development of hepatocellular carcinoma. Studiesnormal ALT levels. Among patients with elevated ALT levels,
there is a weak correlation between the ALT level and histo- in liver transplant recipients with recurrent hepatitis C also
reached opposite conclusions. Two studies reported morelogical diagnosis or histology activity index.64
Serum HCV RNA Level. Regardless of the assay used to severe liver disease in patients with genotype 1b,85,86 but
these findings were not confirmed in another study.87quantify serum HCV RNA levels, all published studies found
no correlation between serum HCV RNA and ALT lev- It is unclear if genotype 1b is more pathogenic. Because a
wide spectrum of liver disease has been found in associationels.8,41,43,65-68 Several studies have reported that blood donors
with normal ALT levels tended to have lower serum HCV with each genotype, genotyping does not help in assessing
the severity of liver disease, and until further data becomeRNA levels than patients with chronic hepatitis C.69-71 How-
ever, other investigators failed to confirm these observa- available, genotyping has no role in predicting prognosis.
tions.43 Data on the correlation between serum HCV RNA
EVALUATION FOR TREATMENTlevel and liver histology are conflicting. Some studies found
no correlation,67,72 one study reported lower serum HCV Once the diagnosis of HCV infection is confirmed and the
severity of liver disease has been assessed, patients shouldRNA levels in patients with more advanced liver disease,12
whereas other studies demonstrated progressive increase in be evaluated for treatment. The decision to treat or not to
treat depends on many factors, including age of the patient,serum HCV RNA levels in patients with more advanced liver
disease.20,65,73 In view of the overlap in serum HCV RNA presence of symptoms, severity of liver disease, likelihood of
response to treatment, concomitant medical problems, andlevels among patients with different stages of liver disease,
quantifying HCV RNA levels in serum will not help in as- contraindications to the use of interferon therapy. In general,
the decision should be made jointly by the physician andsessing the severity of liver disease.
HCV Genotyping. Many investigators have examined the re- patient after the latter has been informed of the pros and
cons of treatment.lation between HCV genotype and severity of liver disease.
Most of the studies have focused on comparisons between The most important factors that have been identified to
be associated with a favorable response to interferon treat-genotype 1b and other genotypes, predominantly types 2
and 3. The vast majority of these studies reported a higher ment are low pretreatment serum HCV RNA level, HCV ge-
notype non-1, and low fibrosis score or lack of cirrhosis.prevalence of genotype 1b among patients with cirrhosis and
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TABLE 2. Correlation Between Pretreatment Serum HCV RNA Levels Thus, it is impractical and unnecessary to exclude patients
and Response to Interferon Therapy from treatment based on genotyping result, although the
results can help in advising patients on the likelihood ofSustained
Biochemical response.
Response (%)
Liver Histology. Liver biopsy is frequently performed to as-No. of
Reference Country Patients bDNA/ bDNA0 sess severity of liver disease before consideration for treat-
ment. Several studies have found that patients with high
Yuki11 Japan 93 33 76 fibrosis score or cirrhosis have lower response rates to inter-
Yamada12 Japan 60 25 63
feron therapy. The results of liver biopsy can help predictMartinot-Peignoux13 France 141 12 39
prognosis and likelihood of response to treatment.58-63Rumi59 Italy 234 11 44
Magrin14 Italy 100 10 33
MONITORING RESPONSE TO TREATMENT
Tsubota61 Japan 185 47 75
Total 813 23 55 The goals of treatment are sustained biochemical (normal-
ization in ALT level) and virological (undetectable HCV RNA
NOTE. Odds ratio, 4.37 (95% confidence interval, 3.12-6.14). in serum) response. It is now recognized that in some pa-
tients there is a discrepancy between biochemical and viro-
logical response100 and that patients who normalize their ALTSerum HCV RNA Level. Every study that has examined the
relation between pretreatment serum HCV RNA level and level but remain HCV RNA positive are more likely to relapse
than those who have normal ALT and undetectable HCVresponse to interferon therapy has concluded that low pre-
treatment serum HCV RNA level is associated with a higher RNA levels.60,101 Because the aim is to determine viral clear-
ance, the most sensitive test (qualitative PCR assay) shouldrate of response.11-14,59,61,88-96 The difference is more striking
when sustained response was compared against transient and be used. bDNA assay has no role in defining virological re-
sponse. The most appropriate time for testing is just beforeno response. Response in most of these studies was defined
as normalization in serum ALT level. In several studies, low completion of treatment. However, there is no data to suggest
that prolonging treatment in patients who have achieved bio-pretreatment serum HCV RNA level was found to be associ-
ated with favorable response regardless of the genotype.88,90,92 chemical but not virological response after 6 to 12 months of
therapy will achieve viral clearance if treatment is prolonged.These findings suggest that all patients considered for treat-
ment should have quantification of serum HCV RNA level. Several studies have shown that early normalization of
ALT level (week 12) is associated with biochemical responseThe results can be used to counsel patients on the likelihood
of response and may influence the patient’s decision on treat- at the end of treatment.102 Continuing treatment at the same
or higher doses in patients who failed to normalize their ALTment. However, there is insufficient data at this stage to
define inclusion or exclusion criteria for treatment based on levels after 12 weeks of interferon treatment at 3-million-
unit doses is associated with very low rate of sustained re-serum HCV RNA level. It is also unclear which assay should
be used for quantification. The bDNA assay is technically sponse.103,104 These data suggest that treatment should be
withdrawn in patients who failed to normalize their ALTeasy, highly reproducible, has good linearity and similar effi-
ciencies for various genotypes, but it is less sensitive; there- levels after 12 weeks of treatment. However, one study re-
ported histological improvement in patients who completedfore, patients who have undetectable HCV RNA in the bDNA
assay would need to be tested by the PCR assay to ascertain a long course (18 months) of interferon therapy despite their
failure to normalize ALT levels.105 This observation needs tothat they are viremic before treatment. Quantitative PCR
assays are more sensitive but tedious to perform, poorly stan- be confirmed before changing our current recommendation
to withdraw treatment based on lack of initial ALT response.dardized, inconsistent, have variable efficiencies for different
genotypes, and have limited range of linearity.97 Recent studies reported an association between rapid viral
clearance and sustained response to interferon therapy.106,107Many published studies used in-house quantitative PCR
assays that are poorly standardized, and the results were In one study, clearance of HCV RNA at week 4 was the
best predictor of sustained biochemical response; HCV RNAexpressed in different units. Studies that used bDNA assays
for quantification of pretreatment serum HCV RNA level became undetectable by week 4 in 73%, 26%, and 0% of the
found that the odds ratio for sustained biochemical response
in patients who were PCR positive but bDNA negative was
4.4 (95% confidence interval, 3.1-6.1) compared with those TABLE 3. Diagnostic Evaluation of Hepatitis C
who were bDNA positive (Table 2).11-14,59,61 Nevertheless,
HCV RNA Assays
sustained biochemical response was achieved in 23% (95%
Qual Quant HCVconfidence interval, 11%-44%) of patients who were bDNA
RIBA PCR PCR bDNA Genotypepositive before treatment. In addition, all except one study12
failed to identify a cut-off value in serum HCV RNA level Confirmation of diagnosis / / { 0 0
Assessment of severity ofabove which response was nil, underscoring the difficulty in
liver disease 0 0 0 0 0using serum HCV RNA level to select patients for treatment.
Evaluation for treatment 0 0 / / 0HCV Genotype. Many studies found that patients with ge-
Determination of responsenotype 1b have lower response rates compared with geno-
to treatment 0 / 0 0 0types 2 and 3.59,61,88,90-99 However, in most countries, geno-
Monitoring progress oftype 1b is the most prevalent genotype. In addition, several
liver disease 0 0 0 0 0
studies found that satisfactory response can be obtained in
Abbreviations: qual, qualitative; quant, quantitative.patients with genotype 1b and low HCV RNA level.12,88,90,92
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patients who had, respectively, sustained, transient, and no liver disease in individuals who are RIBA positive but PCR
negative, the predictive value of pretreatment serum HCVresponse (P Å .02).106 These data suggest that the decision
to discontinue treatment based on failure of initial response RNA level for sustained (biochemical and virological) re-
sponse to interferon treatment, and the criteria for with-may be made earlier by testing for viral clearance. However,
these data were based on small numbers of patients. Further drawal of treatment based on lack of initial response.
studies using more standardized PCR assays are needed to
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